ATE234864T1 - Superagonisten und antagonisten von humanen il-6 und methoden zu deren selektion - Google Patents

Superagonisten und antagonisten von humanen il-6 und methoden zu deren selektion

Info

Publication number
ATE234864T1
ATE234864T1 AT95940409T AT95940409T ATE234864T1 AT E234864 T1 ATE234864 T1 AT E234864T1 AT 95940409 T AT95940409 T AT 95940409T AT 95940409 T AT95940409 T AT 95940409T AT E234864 T1 ATE234864 T1 AT E234864T1
Authority
AT
Austria
Prior art keywords
site
superantagonists
interleukin
superagonists
human
Prior art date
Application number
AT95940409T
Other languages
English (en)
Inventor
Gennaro Ciliberto
Rocco Savino
Armin Lahm
Carlo Toniatti
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Application granted granted Critical
Publication of ATE234864T1 publication Critical patent/ATE234864T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5412—IL-6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G01N33/6869—Interleukin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/14—Lymphokine; related peptides
    • Y10S930/141—Interleukin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
AT95940409T 1994-12-14 1995-12-13 Superagonisten und antagonisten von humanen il-6 und methoden zu deren selektion ATE234864T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM940805A IT1274782B (it) 1994-12-14 1994-12-14 Metodo per selezionare superagonisti, antagonisti e superantagonisti di ormoni del cui complesso recettoriale fa parte gp 130
PCT/IT1995/000216 WO1996018648A1 (en) 1994-12-14 1995-12-13 Superagonists and antagonists of h il-6, and 3d modelling method for their selection

Publications (1)

Publication Number Publication Date
ATE234864T1 true ATE234864T1 (de) 2003-04-15

Family

ID=11402859

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95940409T ATE234864T1 (de) 1994-12-14 1995-12-13 Superagonisten und antagonisten von humanen il-6 und methoden zu deren selektion

Country Status (13)

Country Link
US (2) US5849283A (de)
EP (1) EP0745094B1 (de)
JP (2) JP3206919B2 (de)
CN (1) CN1070866C (de)
AT (1) ATE234864T1 (de)
AU (1) AU702783B2 (de)
CA (1) CA2177838A1 (de)
DE (1) DE69529973T2 (de)
DK (1) DK0745094T3 (de)
ES (1) ES2192585T3 (de)
IT (1) IT1274782B (de)
PT (1) PT745094E (de)
WO (1) WO1996018648A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997016202A1 (en) * 1995-10-27 1997-05-09 Amrad Operations Pty. Ltd. Cytokines and their use in treatment and/or prophylaxis of breast cancer
JP3824173B2 (ja) * 1995-11-07 2006-09-20 株式会社カネカ 自己抗原
IT1285790B1 (it) * 1996-09-24 1998-06-24 Angeletti P Ist Richerche Bio Adenovirus difettivi ricombinanti che codificano per mutanti di interleuchina 6 umana (hil-6) con attivita' antagonista o
AUPO439396A0 (en) 1996-12-24 1997-01-23 Walter And Eliza Hall Institute Of Medical Research, The A method of treatment and prophylaxis
GB9702944D0 (en) * 1997-02-13 1997-04-02 Univ Manchester Reducing fibrosis
EP2011514B1 (de) 1997-03-21 2012-02-29 Chugai Seiyaku Kabushiki Kaisha Präventives oder therapeutisches Mittel mit einem IL-6-Antagonisten als Wirkstoff für durch sensibilisierte T-Zellen vermittelte Erkrankungen
CA2237915A1 (en) 1998-05-19 1999-11-19 Stephen Shaughnessy Osteoporosis treatment
AU753197B2 (en) 1998-07-06 2002-10-10 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for in vitro fertilization
JP4799516B2 (ja) * 1998-08-24 2011-10-26 中外製薬株式会社 Ｉｌ−６アンタゴニストを有効成分として含有する膵炎の予防又は治療剤
US8440196B1 (en) 1998-08-24 2013-05-14 Chugai Seiyaku Kabushiki Kaisha Treatment for pancreatitis using IL-6 receptor antagonist antibodies
US6541244B1 (en) * 1999-06-07 2003-04-01 Cedars-Sinai Medical Center Suppressor of cytokine signaling (SOCS)-3 promoter and methods for its use in genetic therapy in humans
AU7078200A (en) * 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides, comprising il-6 ligand-binding receptor domains and related nucleic acids, antibodies, compositions, and methods of use
UA80091C2 (en) 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
US7247618B2 (en) * 2001-04-30 2007-07-24 Tripathi Rajavashisth Methods for inhibiting macrophage colony stimulating factor and c-FMS-dependent cell signaling
CA2467719C (en) * 2001-11-14 2015-03-17 Jill Giles-Komar Anti-il-6 antibodies, compositions, methods and uses
EP1542719A4 (de) 2001-12-05 2006-06-21 Baylor College Medicine Verfahren und zusammensetzungen zur steuerung der knochenbildung über modulation des sympathikotonus
AU2004212843B2 (en) 2003-02-24 2009-06-25 Chugai Seiyaku Kabushiki Kaisha Remedy for spinal injury containing interleukin-6 antagonist
GB2401040A (en) 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
MY149856A (en) 2003-10-17 2013-10-31 Chugai Pharmaceutical Co Ltd Therapeutic agent for mesothelioma
US20050100550A1 (en) * 2003-11-10 2005-05-12 Mohit Trikha Anti-angiogenic uses of IL-6 antagonists
AR048210A1 (es) 2003-12-19 2006-04-12 Chugai Pharmaceutical Co Ltd Un agente preventivo para la vasculitis.
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
US8470316B2 (en) 2005-10-14 2013-06-25 Chugai Seiyaku Kabushiki Kaisha Agents for suppressing damage to transplanted islets after islet transplantation
US8945558B2 (en) 2005-10-21 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Methods for treating myocardial infarction comprising administering an IL-6 inhibitor
AR057582A1 (es) 2005-11-15 2007-12-05 Nat Hospital Organization Agentes para suprimir la induccion de linfocitos t citotoxicos
TW200803894A (en) 2005-11-25 2008-01-16 Univ Keio Prostate cancer therapeutic agents
US8771686B2 (en) 2006-01-27 2014-07-08 Chugai Seiyaku Kabushiki Kaisha Methods for treating a disease involving choroidal neovascularization by administering an IL-6 receptor antibody
EP2025346B1 (de) 2006-04-07 2016-08-10 Osaka University Mittel zur förderung der muskelregeneration
US9725514B2 (en) 2007-01-23 2017-08-08 Shinshu University Chronic rejection inhibitor
TWI528973B (zh) 2008-06-05 2016-04-11 Chugai Pharmaceutical Co Ltd Nerve infiltration inhibitor
US8188235B2 (en) 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
WO2011149046A1 (ja) 2010-05-28 2011-12-01 独立行政法人国立がん研究センター 膵癌治療剤
HRP20221490T1 (hr) 2010-05-28 2023-02-03 Chugai Seiyaku Kabushiki Kaisha Poboljšanje antitumorskog odgovora t stanice
KR102116202B1 (ko) 2010-11-08 2020-05-28 제넨테크, 인크. 피하 투여용 항―ｉｌ―6 수용체 항체
WO2014200018A1 (ja) 2013-06-11 2014-12-18 独立行政法人 国立精神・神経医療研究センター 再発寛解型多発性硬化症（ｒｒｍｓ）患者の治療予後予測方法、及び新規治療適応判断方法
EP2898896A1 (de) 2014-01-22 2015-07-29 Université Pierre et Marie Curie (Paris 6) Mittel zur Verwendung bei der Behandlung von Netzhautentzündung
TWI805046B (zh) 2015-02-27 2023-06-11 日商中外製藥股份有限公司 Il-6受體抗體用於製備醫藥組成物的用途
US20190060286A1 (en) 2016-02-29 2019-02-28 University Of Florida Research Foundation, Incorpo Chemotherapeutic Methods
EP3620531A4 (de) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry Verfahren zur vorhersage und beurteilung der therapeutischen wirkung bei erkrankungen im zusammenhang mit il-6 und neutrophilen
WO2019151418A1 (ja) 2018-01-31 2019-08-08 元一 加藤 Ｉｌ－６阻害剤を含有する喘息の治療剤
JP7501876B2 (ja) 2019-04-17 2024-06-18 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU687763B2 (en) * 1992-10-20 1998-03-05 Central Laboratory Of The Netherlands Red Cross Blood Transfusion Service Interleukin-6 receptor antagonists
IT1263022B (it) * 1992-11-06 1996-07-23 Angeletti P Ist Richerche Bio Interleuchina-6 mutante con attivita' biologica migliorata rispetto all'interleuchina-6 selvatica.

Also Published As

Publication number Publication date
JP3206919B2 (ja) 2001-09-10
DK0745094T3 (da) 2003-06-10
CN1140456A (zh) 1997-01-15
EP0745094A1 (de) 1996-12-04
DE69529973D1 (de) 2003-04-24
JPH09502460A (ja) 1997-03-11
ITRM940805A1 (it) 1996-06-14
EP0745094B1 (de) 2003-03-19
AU4187196A (en) 1996-07-03
JP2001354698A (ja) 2001-12-25
WO1996018648A1 (en) 1996-06-20
ES2192585T3 (es) 2003-10-16
PT745094E (pt) 2003-07-31
JP3286310B2 (ja) 2002-05-27
CA2177838A1 (en) 1996-06-15
AU702783B2 (en) 1999-03-04
HK1011032A1 (en) 1999-07-02
ITRM940805A0 (it) 1994-12-14
US5914106A (en) 1999-06-22
DE69529973T2 (de) 2003-12-04
IT1274782B (it) 1997-07-24
CN1070866C (zh) 2001-09-12
US5849283A (en) 1998-12-15

Similar Documents

Publication Publication Date Title
DE69529973D1 (de) Superagonisten und Antagonisten von Humanen IL-6 und Methoden zu deren Selektion
EP0890642A3 (de) Retrovirus aus der HIV-Gruppe und dessen Verwendung
DE69636720D1 (de) Dem fibroblasten wachstumsfaktor homologer faktor-1(fhf-1) und methoden zu seiner verwendung
ATE404583T1 (de) Funktionelle antagonisten von hedgehog-aktivität
EP1632500A3 (de) An CAML bindendes oberflächen-lymphozyte-receptor, Nukleinsäuren die dafür kodieren und verfharen zur ihre Verwendung
ES535842A0 (es) Un procedimiento para preparar octapeptidos lineales
DE69519748D1 (de) Aus den vorstufen des mage tumor-abstossungsantigen abstammende einzelne peptede, die hla-a2 moleküle komplexieren
ES2063834T3 (es) Tgf-beta 1/beta 2: un nuevo factor del crecimiento-beta transformante quimerico.
GR3033111T3 (en) A methodology for selecting superagonists, antagonists and superantagonists of hormones whose receptor complex includes gp 130.
Tanigaki et al. Identity of the HL-A common portion fragment and human β2-microglobulin
ATE178072T1 (de) Neuartige polypeptide und ihre verwendung
EP0225020A3 (de) Peptide, welche in der Sequenz Einheiten von Aminosäureresten 17 bis 24 von VIP enthalten
PT1148065E (pt) Proteínas de fusão
EP0220063A3 (de) Antihumaninterleukin-1-Antikörper, Verfahren zu seiner Herstellung und seine Anwendung
Leong et al. Cloning and expression of the cDNA for bovine granulocyte-macrophage colony-stimulating factor
ES8207511A1 (es) Un procedimiento para la preparacion de nuevos peptidos.
DK0876610T3 (da) Fremgangsmåde og anvendelse af polypeptid i sædcelle-æg-binding til at foröge eller mindske fertilitet
DE69932804D1 (de) Protein, welches durch einen cystinknoten charakterisiert ist und verfahren zu dessen herstellung
DK0977859T3 (da) Den neurotrofiske faktor NNT-1
MOBERG Is the Pacific an area of speciation for some foliose genera of the lichen family Physciaceae?
DE59207008D1 (de) Klonierung eines neuen mitgliedes der familie der fibroblasten-wachstumsfaktoren (fgf)-rezeptoren
Seippel Fiber optics
Fitch et al. Multiple lymphokine activities are secreted by a cloned murine T helper cell
Altman et al. Construction of T-cell hybridomas secreting distinct antigen-nonspecific lymphokines
ATE432985T1 (de) Polypeptide mit aktivität der stimulierung von neutrophilen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0745094

Country of ref document: EP

REN Ceased due to non-payment of the annual fee